Wall Street expected the world of IoT, and then punished CalAmp when its growth prospects were lower than expected. Wall Street occasionally has a tendency to rush into the next great technology with blinders on, which is sort of what happened with wireless communications solutions company CalAmp ( CAMP 0.76%), a pioneer of Internet of Things (IoT) solutions, which are capable of connecting with other devices to collect and send data. Furthermore, expansion opportunities following the purchase of an 80% interest in the Fisher property next to the Seabee mine may yield increased gold output in the future. The company's all-in sustaining costs of $940 per ounce for its gold production gives the company ample gross margin from the price of physical gold, even with gold's latest swoon. In company-specific terms, Silver Standard is benefiting from lower costs at its silver Pirquitas mine, which is winding down operations, while at the same time it's enjoying increased cash flow from the Seabee Mine, which came with its purchase of Claude Resources earlier this year. You can also argue that with gold and silver demand outpacing supply, the physical price of gold and silver should be supported. The yields on interest-bearing assets simply aren't attractive enough to chase investors away from owning gold or silver. On a macro level, the opportunity cost of owning physical gold and silver remains relatively low, even with the prospect of the Federal Reserve continuing its monetary tightening and bond yields rising. Johnson & Johnson already ruled out the lower-dose for myelofibrosis due to its lack of efficacy in the IMbark study. The results of these midstage trials for myelofibrosis and myelodysplastic syndromes will determine if Johnson & Johnson advances imetelstat into pivotal late-stage studies.
The company's lead experimental drug, imetelstat, which it licensed to Johnson & Johnson ( JNJ -1.36%) for $35 million in upfront cash, up to $900 million in milestone payments, and sales royalties if approved, is expected to yield top-line data in two phase 2 studies (IMbark and IMerge) next year. GeronĬlinical-stage biotech small-cap Geron ( GERN -1.92%) is poised for a potentially big year. Heading into 2017, there are a number of small-cap stocks ($200 million to $2 billion market cap) that could be worth buying and hanging onto for the long run. If you take your time to weed through a veritable sea of small-cap stocks, you can find some green pasture. In fact, the Vanguard Small-Cap ETF has doubled the year-to-date gains of the S&P 500 through Dec. However, the reality is that small-cap stocks can generate returns that are just as good, if not better, than mid- and large-cap stocks. With quite a few small-caps stocks receiving very little coverage from Wall Street, there aren't enough analysts to argue against that perception. A common misconception about small-cap stocks is that they're volatile and risky.
0 kommentar(er)
